#USA #New York City #biopharmaceuticals #Protalix #H.C. Wainwright

Protalix BioTherapeutics at the Global Investment Conference

Protalix BioTherapeutics, a prominent biopharmaceutical firm listed on NYSE American under the symbol PLX, has announced its participation in the esteemed H.C. Wainwright 27th Annual Global Investment Conference. Scheduled for September 8-10, 2025, this pivotal event will take place at the luxurious Lotte New York Palace Hotel in New York City. The company will be represented by Dror Bashan, who serves as the President and Chief Executive Officer.

Presentation Details

Bashan is set to present on the first day of the conference, specifically on September 8, at 3:30 PM EDT, in the Holmes II Room located on the fourth floor. This engagement promises to be an excellent opportunity for Protalix to highlight its pioneering work in recombinant therapeutic proteins, developed using its unique ProCellEx® plant cell-based protein expression system.

Throughout the event, Protalix's management will also engage in one-on-one meetings with registered investors, focusing on the company's growth trajectory and product pipeline. This personal engagement serves to strengthen investor relationships and provide deeper insights into Protalix's innovative strategies in the biopharmaceutical sector.

About Protalix BioTherapeutics

Protalix distinguishes itself as a frontrunner in the biopharmaceutical landscape, particularly noted for its commitment to advancing the development and commercialization of recombinant therapeutic proteins. Utilizing its proprietary ProCellEx platform, the company revolutionized the production of proteins, becoming the first to receive FDA approval for proteins manufactured using a plant-based expression system. This significant achievement underscores Protalix's role as a pioneer in the industry.

The firm’s flagship product, taliglucerase alfa, approved for treating Gaucher disease, was licensed to Pfizer Inc. for global development and commercialization, with Protalix retaining rights in Brazil. Additionally, the company launched its second product, Elfabrio®, which received approval from both the FDA and the European Medicines Agency in May 2023. This rapid advancement not only showcases Protalix’s innovative potential but also its ability to meet urgent medical needs across markets.

Current Development Pipeline

Protalix has an extensive pipeline that aims to offer proprietary versions of recombinant therapeutic proteins tailored for established pharmaceutical sectors. Among these candidates are PRX-115, a PEGylated uricase targeted at treating uncontrolled gout, and PRX-119, a long-acting DNase I designed to address diseases related to neutrophil extracellular traps (NETs). These promising candidates highlight Protalix’s dedication to leveraging biotechnology for improved health outcomes.

Conclusion

The upcoming conference represents a milestone for Protalix BioTherapeutics, offering essential visibility within the investment community as the company continues to innovate in the biopharmaceutical arena. With a solid pipeline and groundbreaking technologies, Protalix is positioned to make significant contributions to the treatment of various diseases. Investors and stakeholders alike are eagerly anticipating the insights that will arise from this prominent engagement.

For more information about Protalix and its participation in the H.C. Wainwright conference, please contact:

Mike Moyer
Managing Director
LifeSci Advisors
Phone: +1-617-308-4306
Email: [email protected]